

# Index

## A

Acquired immunodeficiency syndrome (AIDS), 52  
Acylation, 181, 182, 186, 188, 190  
Adefovir (ADV), 9  
A3G, 43  
A3H, 45  
A3G, 43  
A3H, 45  
Alisporivir, 66  
Aminoglycosides, 235  
Amphotericin B resistance, 326–328  
Amprenavir, 573, 577, 583, 584  
Aneuploidy, 438  
Antagonism, 534  
Antibiotic discovery, 233  
Antibiotic resistance, 191, 194  
Antibiotic synergy, 239  
Antibiotic tolerance, 209, 212–214  
Antifungal drug resistance, 345–363, 396  
Antimonial resistance, 323–325  
Antiretroviral therapy (ART), 480, 482–484, 536, 567, 577, 591  
Antiviral, 150  
    drug, 90  
    therapy, 140–141  
ART. *See* Antiretroviral therapy (ART)  
*Aspergillosis*, 404  
*Aspergillus*, 347, 349, 351, 353  
    biofilm matrix, 374–375  
    biofilm matrix and drug resistance, 379–380  
*Aspergillus fumigatus*, 404  
    azole resistance genotypes, 408–409  
    azole resistance phenotypes, 408  
    azole resistance selection routes, 409–410  
    clinical implications of azole resistance, 412–414  
    epidemiology of azole resistance, 410–412

    intrinsic versus acquired azole resistance, 407–408  
    molecular basis of environmental resistance, 410  
    phylogeny and subgeneric taxonomy, 405  
    treatment of *A. fumigatus* diseases, 405–407  
*Aspergillus spp.*, 387, 388, 394, 404  
Asunaprevir, 33–34  
Atazanavir, 573, 577, 585, 586, 588, 590  
Attachment inhibitor, 508  
Azole(s), 347–349, 351, 354, 358, 359, 362, 429  
    efflux, 436  
    import, 431

## B

Bacteria, 204, 205, 212, 246  
Beta-lactam, 178  
Beta-lactamase, 181, 183, 186, 188, 190, 194  
Biofilms, 204, 212, 439  
Boceprevir, 31–32

## C

*Candida*, 347, 351  
    biofilm matrix, 372–374  
    biofilm matrix and drug resistance, 375–379  
*Candida spp.*, 386, 388  
CCR5, 503, 507, 510  
CD4, 501  
Cenicriviroc, 510  
Chloroquine resistance, 294–304  
Cholesterol, 437  
Chronic infections, 204, 206, 216  
Chronic pulmonary aspergillosis (CPA), 404  
Cleavage sites (CS), 571, 572, 580  
Clinical outcome, 469–470

Clinical significance, 95–98, 104–107  
 Collateral sensitivity, 246  
 Combination therapy, 582, 584, 585  
 Compensatory fixation, 460  
 Coreceptor inhibitor, 508, 509  
 Cross-resistance, 537  
*Cryptococcus*, 347, 351  
 Crystal structure, 160, 165  
 CXCR4, 503  
 Cyclophilin A (CypA), 63  
 CYCLOPHILIN Inhibitors, 77–78  
 Cyclophilins, 64  
*CYP51A*, 391, 392  
 Cytoskeleton, 236

**D**

Darunavir, 573, 586, 588  
 1,3- $\beta$ -D-glucan synthase, 393  
 Direct-acting antivirals, 61, 70  
 Drug efflux, 218  
 Drug resistance, 47, 123–141, 265–266,  
 270–273, 479–493, 527–528

**E**

Echinocandins, 349, 351, 356, 359, 361, 395, 441  
 Efflux pumps, 388, 391  
 Enfuvirtide/T-20 506  
 Entecavir (ETV), 9  
 Entry cascade, 501  
 Envelope, 508  
 Ergosterol, 434  
 Evolution, HIV, 568–569  
 Experimental evolution, 356–358  
 Extended spectrum  $\beta$ -lactamases (ESBLs), 183  
 Extracellular DNA, 379  
 Extracellular matrix, fungal biofilms, 371–375,  
 379  
 Extracellular polymeric matrix, 205

**F**

Fitness, 358–359  
*FKS*, 394  
 5-fluorocytosine (flucytosine/5-FC), 441  
 Function mutation, gain of, 433  
 Fungal pathogens, 346, 347, 357, 362  
 Fusion inhibitor, 507

**G**

Gag, 569, 571, 572, 574  
 Gene conversions, 437–438

Genetic barrier, 126, 127, 131, 132, 134, 135  
 Genomics, 234  
 Genotypic testing, 91–92, 100–101, 109

**H**

HBV replication, 17  
 HCV NS3/4A, 164  
 Heat shock proteins, 339–440  
 Hepatitis B virus (HBV), 4, 13  
 Hepatitis C virus (HCV), 60, 126, 128, 129,  
 136, 138  
   asunaprevir, 33–34  
   boceprevir, 31–32  
   NS3-4A protease, 23–25  
   paritaprevir, 34  
   simeprevir, 32–33  
   telaprevir, 29–31  
 Herpes simplex virus (HSV), 91–100  
 Herpesvirus, 88  
 High genetic barrier, 72  
 HIV-1. *See* Human immunodeficiency virus  
   type, 1 (HIV-1)  
 Host factors, 73  
 Host-targeting antivirals, 61–62  
 Hsp90, 354, 355, 360, 362  
 Human cytomegalovirus (HCMV), 100–101  
 Human immunodeficiency virus type, 1  
   (HIV-1) 128, 130, 132, 135, 479–493,  
   524, 567–591  
   PI development, 573  
   prevention, 480, 493  
   protease, 151  
   protease resistance, 575–581  
 Hypermutations, 50

**I**

Ibalizumab, 502, 508  
 Immunocompromised patient, 92, 96, 97  
 Invasive aspergillosis (IA), 405  
 Invasive fungal infections (IFIs), 386

**L**

$\beta$ -lactamase, 243  
 $\beta$ -lactams, 239, 242  
 Lamivudine (LMV), 4, 5  
 Leishmaniasis treatment, 313–334

**M**

Malaria, 290, 306  
 Management, 98–100, 107–109

- Maraviroc, 505  
Matrix glucan and drug sequestration, 376–377  
Matrix glucan  
  production and modification, 377–378  
  regulation, 378–379  
Mechanism of resistance, 579  
Microevolution, 346  
Miltefosine resistance, 330–332  
Minor variant drug resistance, 484, 485, 487–490  
Minority variants, 470–473  
Mitochondrial loss, 436  
Mobile genetic elements, 182, 183, 187  
Molecular diagnosis, 395  
Molecular dynamics, 161  
Molecular epidemiology, 467–468  
Multi-drug resistant tuberculosis, 263–281  
Multidrug-resistance (MDR) efflux pumps, 193  
Muropeptides, 191  
Mutagenesis, 46, 50  
Mutant spectrum, 125, 128, 137, 138  
Mutations, 91, 93–95, 101–104, 528
- N**  
Natural products, 234–236  
Next generation sequencing, 472  
Nonnucleoside inhibitor, 526  
Non-structural protein 3 (NS3), 23–24  
NS5A, 66, 76  
Nucleoside inhibitor, 525
- O**  
Oxazolidinones, 233
- P**  
Paritaprevir, 34  
Paromomycin resistance, 328–330  
Pegylated interferon alfa (PEG-IFN), 24, 25  
Penicillin binding proteins (PBPs), 178, 187, 188  
Peptidoglycan (PG), 178, 191  
  recycling, 191  
Persists, 245  
PfCRT, 296–299  
Phenotypic testing, 91–92, 100–101  
Physiologic heterogeneity, 209–210  
*Plasmodium falciparum*, 296–301  
Polyenes, 441  
Porins, 192  
Pre-exposure prophylaxis (PrEP), 479–493  
Prevalence transmitted drug resistance,  
  460–461, 463  
Primary resistance assessment, 387  
Primary resistance. *See* Transmitted drug  
  resistance (TDR)  
PRO-140, 506  
Protease, 567–591  
Protease inhibitors (PIs), 29–35, 567–591  
*Pseudomonas aeruginosa*, 204, 206, 207, 209,  
  211, 212, 214, 216, 217, 219
- Q**  
Quinoline multidrug resistance, 291–294  
Quorum sensing signaling, 205
- R**  
Replication rate, 128  
Replicative capacity, 457, 459, 461, 469  
Rescue therapy, 13  
Resistance, 59–79, 91–92, 568–569, 575–581  
  drug-related parameters, 28  
  host-related parameters, 28–29  
  protease inhibitor, 29–35  
  virus-related parameters, 25–28  
Resistance associated variant, 25–27  
Resistance reversal agents, 332–333  
Resistome, 232, 246–247  
Restriction factor, 45, 50  
Reverse transcriptase (RT), 47, 523–537  
Reverse transcription, 5  
Ribavirin, 24
- S**  
Secondary metabolites, 234  
Secondary resistance, 386–395  
Second line tuberculosis drugs, 266  
Siderophore conjugates, 194  
Simeprevir, 32–33  
Species identification, 387  
Sterol, 427  
Sterol import, 437  
Stress response, 210, 212–214, 351, 352,  
  354–355, 360, 361  
Substrate envelope, 155  
Subtype viruses, 535–536  
Sulfonamides, 236  
Surveillance, 462, 466, 473  
Susceptibility, 386, 393
- T**  
Target modification, 187–188  
Telaprevir, 29–31

- Telbivudine (LdT), 9  
Tenofovir disoproxil fumarate (TDF), 10  
Therapy, 568  
Tipranavir, 573, 577, 586, 587  
Transmission capacity, 469  
Transmitted drug resistance (TDR), 536  
    clinical outcome, 469, 470  
    evolution of, 458–460  
    guidelines on, 461–462  
    molecular epidemiology, 467–468  
    prevalence of, 460–461  
Transpeptidase, 178  
Treatment of drug-resistant tuberculosis, 280  
Triazole, 392  
Triazole antifungals, 405  
Tropism, 509  
Tuberculosis, 264  
Tuberculosis treatment, 265–266
- V**  
Vancomycin, 242  
Varicella-zoster virus (VZV), 91–92  
Viral dynamics, 457–458  
Viral evolution, 47, 458–460  
Viral fitness, 12–129, 135, 137  
Viral-host interaction, 52  
Viral load, 128–129, 130, 141  
Viral persistence, 460  
Viral quasispecies, 124–127, 129, 141  
Viral reversion, 460–461